[HTML][HTML] Current and emerging therapeutic approaches for colorectal cancer: A comprehensive review

A Kumar, V Gautam, A Sandhu, K Rawat… - World Journal of …, 2023 - ncbi.nlm.nih.gov
Colorectal cancer (CRC) affects 1 in 23 males and 1 in 25 females, making it the third most
common cancer. With roughly 608000 deaths worldwide, CRC accounts for 8% of all cancer …

[HTML][HTML] Breaking therapy resistance: an update on oncolytic newcastle disease virus for improvements of cancer therapy

V Schirrmacher, S van Gool, W Stuecker - Biomedicines, 2019 - mdpi.com
Resistance to therapy is a major obstacle to cancer treatment. It may exist from the
beginning, or it may develop during therapy. The review focusses on oncolytic Newcastle …

[HTML][HTML] Oncolytic viruses: Immunotherapy drugs for gastrointestinal malignant tumors

Q Li, PK Oduro, R Guo, R Li, L Leng, X Kong… - Frontiers in Cellular …, 2022 - frontiersin.org
Oncolytic virus therapy has advanced rapidly in recent years. Natural or transgenic viruses
can target tumor cells and inhibit tumor growth and metastasis in various ways without …

[HTML][HTML] Coxsackievirus A11 is an immunostimulatory oncolytic virus that induces complete tumor regression in a human non-small cell lung cancer

A Sakamoto, H Inoue, S Miyamoto, S Ito, Y Soda… - Scientific Reports, 2023 - nature.com
Non-small cell lung cancer (NSCLC) is the leading cause of cancer-related mortality
worldwide. Innovative treatment is required to improve overall survival rates for advanced …

[HTML][HTML] Advancements and challenges in oncolytic virus therapy for gastrointestinal tumors

Y Li, H Duan, J Ye - Biomedicine & Pharmacotherapy, 2023 - Elsevier
Background Tumors of the gastrointestinal tract impose a substantial healthcare burden due
to their prevalence and challenging prognosis. Methods We conducted a review of peer …

[HTML][HTML] TP53 mutation influences the efficacy of treatment of colorectal cancer cell lines with a combination of sirtuin inhibitors and chemotherapeutic agents

H Yang, Y Chen, Y Jiang… - Experimental and …, 2020 - spandidos-publications.com
Chemoresistance of colorectal cancer (CRC) leads to tumor recurrence and metastasis and
new strategies are urgently needed to improve the outcomes of conventional chemotherapy …

Immunostimulatory oncolytic activity of coxsackievirus A11 in human malignant pleural mesothelioma

K Okamura, H Inoue, K Tanaka, Y Ikematsu… - Cancer …, 2023 - Wiley Online Library
Malignant pleural mesothelioma (MPM) is an aggressive solid cancer with a poor prognosis,
whereas coxsackievirus A11 (CVA11) is a potential oncolytic virus for cancer treatment. We …

Immuno-oncolytic viruses: emerging options in the treatment of colorectal cancer

SI Kana, K Essani - Molecular Diagnosis & Therapy, 2021 - Springer
Colorectal cancer is the third most common neoplasm in the world and the third leading
cause of cancer-related deaths in the USA. A safer and more effective therapeutic …

[HTML][HTML] Oncolytic virotherapy with SOCS3 enhances viral replicative potency and oncolysis for gastric cancer

S Matsumura, M Nakamori, T Tsuji, T Kato… - Oncotarget, 2021 - ncbi.nlm.nih.gov
Oncolytic virotherapy is an encouraging treatment using herpes simplex virus (HSV) for
gastric cancer patients. To treat gastric cancer, we generated and evaluated the efficacy of …

The Future of Interventions for Stage IV Colorectal Cancers

S Lloy, M Lin, J Franko, S Raman - Clinics in Colon and Rectal …, 2023 - thieme-connect.com
Future options for the management of stage IV colorectal cancer are primarily focused on
personalized and directed therapies. Interventions include precision cancer medicine …